ArticleTanaffos2025
Persons at High-Risk and Low-Risk for Chronic Obstructive Pulmonary Disease: Results from the BOLD Study in Iran.
Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a common, heterogeneous, and largely preventable respiratory condition that is frequently undiagnosed until advanced stages. We estimated the prevalence of COPD risk categories in Iran and examined factors associated with high-risk status. Materials and Methods: A population-based survey using stratified cluster sampling was conducted in five major Iranian provinces, representing approximately 36% of the national population. Non-institutionalized adults aged ≥18 years completed standardized questionnaires, SF-12 health-related quality-of-life assessments, and pre- and post-bronchodilator spirometry under the tailored Burden of Lung Disease protocol. Participants were classified as diagnosed COPD (DN), high risk (HR; ≥10 years of tobacco use plus ≥1 respiratory symptom), or low risk (LR). Results: Among 533 participants (mean age, 53.2 ± 1.83 years; 43.9% men), 5.0% (95% CI: 3.17-6.83) had diagnosed COPD, 13.2% (95% CI: 12.92-13.48) were high risk, and 81.8% (95% CI: 78.55-85.05) were low risk. Dyspnea on exertion (43.6%), productive cough (27.1%), and frequent shortness of breath (32.1%) were common and occurred more frequently in DN and HR groups. High-risk status was more prevalent among men, current smokers, and adults aged >45 years. Tobacco use for ≥10 years was strongly associated with HR classification. Smoking patterns and symptom burden varied substantially across provinces. DN and HR participants had significantly poorer SF-12 physical and mental health scores than LR participants (P<0.001). Conclusion: A substantial proportion of Iranian adults are at high risk for COPD, indicating an important burden of potentially undiagnosed disease. Targeted screening, smoking-cessation initiatives, and earlier primary-care intervention may improve COPD detection and prevention.
Indexed as
Identifiers
42757361PMC13585154What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.